Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT03323944 | CAR T Cell Immunotherapy for Pancreatic Cancer | Phase 1 | terminated | Oct 27, 2017 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Nov 25, 2020 | Ascentage Pharma Group Inc. | Company Strategy | Sponsor / business decision |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT06199466 | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With… | Phase 1 | terminated | Jan 10, 2024 | M.D. Anderson Cancer Center | \<75 % participation | Other (stated, no rule matched) |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | Phase 2 | terminated | Nov 9, 2021 | Ludwig-Maximilians - University of Munich | Low accrual, close out in November 2025 | Enrollment / accrual |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | Phase 2 | terminated | Apr 14, 2021 | Lahey Clinic | The study closure was initiated by the financial sponsor and agreed upon by the site PI. The study… | Enrollment / accrual |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and…(CLAUDIO-01) | Phase 1 / Phase 2 | terminated | Sep 1, 2022 | SOTIO Biotech a.s. | Trial terminated by Sponsor based on benefit- risk reassessment | Other (stated, no rule matched) |
| NCT07026916 | A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic… | Phase 2 | withdrawn | Jun 18, 2025 | Genfleet Therapeutics (Shanghai) Inc. | Adjustment of Product Development Strategy | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following… | Phase 1 / Phase 2 | terminated | Oct 6, 2023 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT03417921 | A Study of ABTL0812 in Pancreatic Cancer(Pancreatic) | Phase 1 / Phase 2 | suspended | Jan 31, 2018 | Ability Pharmaceuticals SL | We opened another study. | Other (stated, no rule matched) |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | Phase 2 | terminated | Oct 28, 2019 | University of Nebraska | Due to low accrual and futility | Efficacy / futility |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | N/A | terminated | Feb 25, 2014 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant… | Phase 1 | withdrawn | Dec 2, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | Phase 2 | terminated | Aug 5, 2021 | Ohio State University Comprehensive Cancer Center | Principal investigator departed sponsoring organization | Investigator |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | Phase 1 | withdrawn | Nov 27, 2024 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients… | Early Phase 1 | terminated | May 3, 2023 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT05657418 | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic… | Phase 1 | terminated | Dec 20, 2022 | Shanghai Junshi Bioscience Co., Ltd. | Company research and development strategy adjustment | Sponsor / business decision |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Lisata Therapeutics, Inc. | Management Decision | Other (stated, no rule matched) |
| NCT00529113 | Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer | Phase 1 | terminated | Sep 14, 2007 | Biogen | To pursue other indications | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | — | withdrawn | Mar 18, 2022 | Beth Israel Deaconess Medical Center | Lack of funding | Funding |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Phase 4 | terminated | Oct 11, 2023 | Brian Anderson, MD | Slow Accrual | Enrollment / accrual |
| NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic… | Phase 2 | terminated | Jul 16, 2021 | OHSU Knight Cancer Institute | low enrollment | Enrollment / accrual |
| NCT02047500 | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer | Phase 1 | terminated | Jan 28, 2014 | ImmunoGenesis | The trial has been terminated earlier following the company decision to discontinue the clinical… | Sponsor / business decision |
| NCT01834235 | QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat… | Phase 1 / Phase 2 | terminated | Apr 17, 2013 | Precision Biologics, Inc | DSMB terminated the trial for futility. | Efficacy / futility |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Dec 18, 2019 | Helix BioPharma Corporation | The primary reason for early termination was budget constraint. | Funding |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following… | Phase 2 | terminated | Feb 22, 2022 | Washington University School of Medicine | Investigator and study team chose to end study early. | Investigator |
| NCT01555489 | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard… | Phase 2 | terminated | Mar 15, 2012 | Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With… | — | withdrawn | Apr 10, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | No subjects were enrolled. Study team was not able to grow cell lines for the tumors. | Enrollment / accrual |
| NCT03820544 | SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary… | N/A | terminated | Jan 29, 2019 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Interest in this study changed and it was decided to end enrollment early | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials